It is noteworthy that the novel NQO2-non-kinase-mediated AKT control unraveled in this study differs significantly from traditional PTEN/PI3K mediated AKT control [43]–[45]; namely, the inhibition of AKT by over-expressing NQO2 in PTEN-deficient cancer cells can be expected to inhibit tumor growth. This evidence concerns the gene AKT1 and cancer.